BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. PROPERTIES
Corporate Headquarters and other office space
Our U.S. corporate headquarters are located in leased premises at 1325 Avenue of the Americas, 28th Floor, New York, NY 10019. We also lease office space in Burlington, Massachusetts. Additionally, our Israeli subsidiary is party to a lease agreement for approximately 950 square meters of office and laboratory space located at 12 Basel Street, Petach Tikva, Israel.
We believe that the current office, laboratory space are adequate to meet our needs for research and development and administrative operations.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.